

REMARKS

The Notification of Missing Requirement Under 35 U.S.C. 371 stated that an oath or declaration identifying the application by the international application number and international filing date has not been submitted. This is respectfully traversed.

An executed declaration identifying the application by the international application number and international filing date was submitted on June 29, 2004. Enclosed is a copy of the previously-submitted declaration.

The Notification also requested a corrected Sequence Listing. In response, Applicants enclose a paper copy and a computer readable form of a corrected Sequence Listing. The content of the paper copy and of the computer readable form is the same.

The corrected Sequence Listing contains two additional sequences, i.e., SEQ ID NOS: 17 and 18, which are identical to SEQ ID NOS: 1 and 2, respectively, except that the signal peptide has been corrected to be two amino acids longer. This is an inherent property of the endoglucanase, which is encoded by the DNA sequence contained in *E. coli*, DSM 14541, which Applicants deposited under the Budapest Treaty. Thus, this submission contains no new matter.

Because a declaration was timely submitted, Applicants submit that no fee is required. If a fee is required, please charge the fee to Novozymes North America, Inc., Deposit Account No. 50-1701.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: January 18, 2005



Elias J. Lambiris, Reg. No. 33,728
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097